NCRI Press Release, 9 November 2016
Date published: Apr 03 2018
Marker for aggressive prostate cancer doubles-up as a drug target
Download the attachmentRecent Tweets
-
Didn't get a chance to join us at last week's #NCRIVirtual webinar? Don't worry, the recording for 'In conversation… https://t.co/OqwjPvehHA
12 hours ago -
RT @BreastDocUK : Another excellent #NCRIVirtual webinar today at 4.30pm BST (10.30 CT) @EricTopol in conversation with Tim Maughan Covid, c…
14 hours ago -
⏰ There's still time to register! ⏰ At 16:30 (BST) today we're hosting the next #NCRIVirtual webinar: 'In conversat… https://t.co/d9UzlC7YoD
17 hours ago
- 19 Mar 2020Workstream leads: NCRI Skin Group
- 26 Nov 2019CM-Path - Application for Consumer Membership (Deadline - 1st January 2020)
- 20 Nov 2019With its new chair, Professor David Harrison, at the helm, CM-Path share top priorities
- 19 Jul 2019Consumer (Patient / Carers) vacancies for NCRI Groups available. Apply today!
- 20 May 2019Celebrating ten years of NCRI’s Clinical and Translational Radiotherapy Research Group
- 29 Apr 2019NCRI and The British Society for Immunology announce new partnership
- 14 Mar 2019Register now for the NCRI CTU Annual Trials Meeting: 17 June 2019
RSS Feed